BEVERLY, MA–(Marketwire – May 9, 2011) – Cellceutix Corporation (OTCQB: CTIX), is pleased to report that it has submitted for review the “Investigator’s Brochure and Clinical Protocol” sections of its Investigational New Drug (IND) application for Kevetrin™, Cellceutix’s drug in development as a treatment for cancers, to the world-renowned hospital in which it expects to host its Phase I clinical trials. Upon review by the cancer center, Cellceutix will add the documents to the IND for submission to the FDA.
Leo Ehrlich, CEO of Cellceutix, stated, “I would like to congratulate the Cellceutix team including our many consultants, shareholders, and vendors on this important event. Yes, many thought it was impossible to accomplish what we have achieved. Not only have we have created a new chemical class and breakthrough in medicine; we completed this at amazing speed, about three years, and expect shortly to file our IND. We are working diligently to see Cellceutix flourish and believe the best is yet to come.”